Plug Pulled on Novel Schizophrenia Tx; Buprenorphine Plan Halted

(MedPage Today) -- After its investigational adjunctive schizophrenia treatment CTP-692 (D-serine) flopped in a phase II study, Concert Pharmaceuticals said it's throwing in the towel.
In 2019, about one-third of fatal heroin and fentanyl overdoses...